Proposal

Background

Lyssencephaly

•Smooth brain (froom the Greek “lissos” and “enkhapalos”)

•Cerebral cortex scarces of:▫Gyri▫Groove▫Fissures

•Malformation of the physical structure is because it didn’t developed completely while embryonic development.

•Lack of embryonic development:▫Low blood flow▫Congenic Citomegalovirus (cCMV)▫Genetic mutation (LIS1, XLIS)

ResearchesMalformations of cortical development in children with congenital cytomegalovirus infection - A study of nine children with proven congenital cytomegalovirus infection

•Development of Lissencephaly in the fetus as direct consequence of early infection.

•Most common vertically transmitted disease ▫rate of the infection ranging:

0.2 to 2.4% in newborn infants 40.000 infants per year

Chemical remedyOral Hexadecyloxypropyl-Cidofovir Therapy in Pregnant Guinea Pigs Improves Outcome in the Congenital Model of Cytomegalovirus Infection •Alternative orally supply analog of the

existing drug, Cidofovir•Only proved effiency of Guinea Pigs

Why supply antibodies?

Seroprevalence of cytomegalovirus in-fection in pregnant women and associ-ated role in obstetric complications: a

preliminary study

IgGIgM

Hypothesis

The augment of antibodies IgG and IgM may reduce the presence of CVM, representing a minor risk to the fetus in developing Lissencephaly.

Objectives

• Develop a treatment with antibodies against the growth of Citomegalovirus that causes Lyssencephaly• Reduce the CMV presence in the

placenta• Lower the risks of developing

Lissencephaly caused by cCMV.

Methodology

Materials

•CMV Pp38 (UL80a), Cytomegalovirus Antigen, Recombinant

•IgM Antibody, mAb, Mouse•Mouse IgG control (Whole Molecule),

Purified•IL-4 Antibody (2G6A8), mAb, Mouse•Mouse IL-28A/B •39 female pregnant Mus Musculus•Image Cytometri

•Light diagnostics CMV direct Immunofluorescence Assay Kit

•Dextran Leukocyte Separation Kit •Formaldehyde-Noidet P-40•MRI

Methodology

Step: Prepare research models

Prepare research models

•Mice from 12-13 days•Anesthiaze mice•Inject with CMV vector solution with a

glass micropipette•Place pipette for an 30 s and then slowly

withdrawn.

Research model’s distribution

• Groups:▫ IL 6▫ IL 28▫ IgG▫ IgM

• Sub-groups:▫ A= every week▫ B= every 48 hrs▫ C= every three

days

Mus musculu

s

Group 1

sub-group A

sub-group B

sub-group C

Group 2

sub-group A

sub-group B

sub-group C

Group 3

sub-group A

sub-group B

sub-group C

Step: Viral presence assays

Extract serology: CVS

•Placenta is the common path •Chronic Villous Sampling

▫Suction of a tissue from placenta

Step: ELISPOT

•Quantify presence of IgG and IgM in all experimental groups

•Procedure according to:▫“General ELISPOT procedure” by

abcam.com

Step: Direct immunofluorescence

•Cualitative presence of IgG and IgM in all experimental groups

•Process according to:▫“Immunostaining of cells in tissue culture”

by ENCORE biotechnology INC.

Spected results

•ELISPOT will indicate:▫ augment in antibodies in experimental

groups will mean lower presence of CMV

•Direct immunofluorescence:▫Control group will be brighter than

experimental groups will mean high presence of CMV

Bibliography • Bosnjak VM, Daković I, et al. Malformations of

cortical development in children with congenital cytomegalovirus infection - A study of nine children with proven congenital cytomegalovirus infection. January, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21648339

• Ravo FJ, Bernstein DI, et al. Oral Hexadecyloxypropyl-Cidofovir Therapy in Pregnant Guinea Pigs Improves Outcome in the Congenital Model of Cytomegalovirus Infection. November 15, 2011. http://www.ncbi.nlm.nih.gov/pubmed?term=Oral%20Hexadecyloxypropyl-Cidofovir%20Therapy%20in%20Pregnant%20Guinea%20Pigs%20Improves%20Outcome%20in%20the%20Congenital%20Model%20of%20Cytomegalovirus%20Infection%20

• Araswathy TS, Az-Ulhusna A, et al. Seroprevalence of cytomegalovirus infection in pregnant women and associated role in obstetric complications: a preliminary study. March, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21710852

• Kaneda K, Kasahara H, et al. Selective Optical Control of Synaptic Transmission in the Subcortical Visual Pathway by Activation of Viral Vector-Expressed Halorhodopsin. April 5, 2011. http://www.ncbi.nlm.nih.gov/pubmed?term=Selective%20Optical%20Control%20of%20Synaptic%20Transmission%20in%20the%20Subcortical%20Visual%20Pathway%20by%20Activation%20of%20Viral%20Vector-Expressed%20Halorhodopsin

• Boeckh, M. and Boivin, G. Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications. Clinical Microbiology Reviews, July 1998, p. 533-554, Vol. 11, No. 3. http://cmr.asm.org/cgi/content/full/11/3/533